OVARIAN MALIGNANT MIXED MULLERIAN TUMORS TREATED WITH PLATINUM-BASED CHEMOTHERAPY

被引:42
作者
BICHER, A
LEVENBACK, C
SILVA, EG
BURKE, TW
MORRIS, M
GERSHENSON, DM
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GYNECOL ONCOL,HOUSTON,TX 77030
关键词
D O I
10.1016/0029-7844(95)00038-S
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To characterize the clinical course of patients diagnosed with ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Methods: Thirty-six patients received this treatment at The University of Texas M. D. Anderson Cancer Center in the period 1979-1993. The mean age was 59 years. Stage distribution was as follows: stage IA, one (3%) patient; stage IIIB, two (5.5%); stage IIIC, 21 (58%); and stage IV, two (5.5%). Ten (28%) patients were unstaged. Chemotherapy regimens included cisplatin, doxorubicin, and cyclophosphamide in 16 patients; cisplatin-ifosfamide in five; cisplatin-cyclophosphamide in four; carboplatinum in three; cisplatin-doxorubicin in three; and various other combinations in the remaining five. Results: Of 16 patients evaluated for clinical response, seven (44%) had a complete response and four (25%) had a partial response, for a total clinical response rate of 69%. Nine patients were evaluated for surgical response: five (56%) had a complete response and one (11%) had a partial response, for a total surgical response rate of 67%. The median survival for the cohort was 18 months. At the time of this analysis, five (14%) patients were alive and disease-free, 25 (69%) had died of disease, five (14%) were alive with disease, and one had been lost to follow-up. Conclusion: This study suggests that the clinical course of patients with ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy is similar to the clinical course experienced by patients with high-grade epithelial carcinoma of the ovary.
引用
收藏
页码:735 / 739
页数:5
相关论文
共 14 条
[1]   PLATINUM-BASED COMBINATION CHEMOTHERAPY FOR MALIGNANT MIXED MESODERMAL TUMORS OF THE OVARY [J].
ANDERSEN, WA ;
YOUNG, DE ;
PETERS, WA ;
SMITH, EB ;
BAGLEY, CM ;
TAYLOR, PT .
GYNECOLOGIC ONCOLOGY, 1989, 32 (03) :319-322
[2]   PROSPECTIVE TRIAL OF CISPLATIN, ADRIAMYCIN, AND DACARBAZINE IN METASTATIC MIXED MESODERMAL SARCOMAS OF THE UTERUS AND OVARY [J].
BAKER, TR ;
PIVER, MS ;
CAGLAR, H ;
PIEDMONTE, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (03) :246-250
[3]  
BARAKAT RR, 1992, OBSTET GYNECOL, V80, P660
[4]  
CARLSON JA, 1983, CANCER, V52, P1473, DOI 10.1002/1097-0142(19831015)52:8<1473::AID-CNCR2820520823>3.0.CO
[5]  
2-O
[6]  
DEHNER LP, 1971, CANCER, V27, P207, DOI 10.1002/1097-0142(197101)27:1<207::AID-CNCR2820270129>3.0.CO
[7]  
2-0
[8]  
DINH TV, 1988, OBSTET GYNECOL, V72, P409
[9]  
Hanjani P, 1983, Obstet Gynecol Surv, V38, P537, DOI 10.1097/00006254-198309000-00002
[10]  
Hernandez W, 1977, Obstet Gynecol, V49, P59